Understanding how Sirtuin 5 affects kidney injury
The role of Sirtuin 5 in acute kidney injury
This study is looking at a protein called Sirtuin 5 to see how it helps protect kidney cells from damage during acute kidney injury, which can happen from things like certain chemotherapy treatments or lack of blood flow, with the hope of finding new ways to keep kidneys healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10829351 on NIH RePORTER |
What this research studies
This research investigates the role of Sirtuin 5, a protein that may influence kidney cell metabolism, in the context of acute kidney injury (AKI). The study aims to uncover the mechanisms by which Sirtuin 5 protects kidney cells from damage caused by conditions like ischemia-reperfusion injury and certain chemotherapy drugs. By using animal models and human kidney cells, researchers will explore how manipulating Sirtuin 5 levels can potentially prevent or reduce kidney damage. The ultimate goal is to develop new therapies that can limit the impact of AKI and prevent progression to chronic kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute kidney injury, particularly those at risk of progressing to chronic kidney disease.
Not a fit: Patients with chronic kidney disease who have not experienced acute kidney injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect kidney function and improve recovery for patients experiencing acute kidney injury.
How similar studies have performed: Previous research has shown promising results in understanding the role of mitochondrial function in kidney injury, suggesting that this approach may yield valuable insights.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Sims-Lucas, Sunder — University of Pittsburgh at Pittsburgh
- Study coordinator: Sims-Lucas, Sunder
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.